High dose rate brachytherapy as monotherapy for localised prostate cancer

Strouthos, Iosif; Tselis, Nikolaos; Chatzikonstantinou, Georgios; Butt, Saeed; Baltas, Dimos; Bon, Dimitra; Milickovic, N.; Zamboglou, Nikolaos

doi:10.1016/j.radonc.2017.09.038

Cited by 35 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For our analysis we considered a dose prescription per implant of 11.5 Gy, defined as aimed D 90 for the PTV, according to the Offenbach protocol for HDRBT monotherapy for prostate cancer with three implants and a single fraction per implant. [9][10][11]40 The default HIPO optimization settings for our optimization runs, adhered to the Offenbach protocol, are depicted in Table I. In the last step of the optimization, the HIPO solutions were further fine-tuned in terms of dwell time optimization by adjusting the importance factor for PTV (PTV low objective).…”

Section: F Treatment Planningmentioning

confidence: 99%

“…Comparing the initial catheter configurations generated by the three different methods for all 15 implants it was found that the catheters of the CCVT initial plans differ in nine (median value with a range of 3-17) positions (template holes) when compared to those of the CVT-based plans, where this was for 13 catheter positions (medial value, range 8-21) when compared to initial plans generated using the default initialization of HIPO. On the other hand, the CVT-based plans differ in 12 catheter positions (median value, range [8][9][10][11][12][13][14][15][16][17][18][19][20] when compared to the corresponding initials plans with the default HIPO initialization.…”

Section: A Constrained Cvt-vs Cvt-based Initial Plansmentioning

confidence: 99%

“…This was for 11 catheters (median value, range 7-20) the case, when compared to final plans generated using the default initialization of HIPO. On the other hand, the HIPO CVT_adaptive plans differed in ten catheter positions (median value, range [6][7][8][9][10][11][12][13][14][15][16][17][18], when compared to corresponding final HIPO default_adaptive plans.…”

Section: D1 Hipo Execution In Adaptive Modementioning

confidence: 99%

“…[1][2][3][4] HDRBT is often used either as a local dose escalation technique in a boost set-up in combination with external beam radiotherapy (EBRT) for intermediate-and high-risk-PCA [5][6][7][8] or as monotherapy for localized prostate cancer (low-intermediate risk and selective high-risk PCA cases). [9][10][11][12][13][14][15] During the last two decades, significant innovations such as improved ultrasound (U/S) image quality, high resolution three-dimensional (3D) U/S volume acquisition, and catheter reconstruction on live U/S-imaging have been achieved in the field of 3D intraoperative ultrasound HDR-BT for PCA. 16 Commercial solutions are available enabling different scenarios of intraoperative ultrasound based implantation, treatment planning and treatment delivery (Prostate Module in SagiPlan â *, Oncentra Prostate â † , and Vitesse TM, ‡ ).…”

Section: Introductionmentioning

confidence: 99%

“…Hybrid inverse planning optimization (HIPO) parameter settings according to the Offenbach protocol [9][10][11]40. …”

mentioning

confidence: 99%

See 4 more Smart Citations

Investigating the role of constrained CVT and CVT in HIPO inverse planning for HDR brachytherapy of prostate cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Section: F Treatment Planningmentioning

confidence: 99%

Section: A Constrained Cvt-vs Cvt-based Initial Plansmentioning

confidence: 99%

Section: D1 Hipo Execution In Adaptive Modementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Hybrid inverse planning optimization (HIPO) parameter settings according to the Offenbach protocol [9][10][11]40. …”

mentioning

confidence: 99%

See 3 more Smart Citations

Investigating the role of constrained CVT and CVT in HIPO inverse planning for HDR brachytherapy of prostate cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: High-dose-rate brachytherapy (HDR BRT) has been enjoying rapid acceptance as a treatment modality offered to selected prostate cancer patients devoid of risk group, employed either in monotherapy setting or combined with external beam radiation therapy (EBRT) and is currently one of the most active clinical research areas.Recent findings: This review encompasses all the current evidence to support the use of HDR BRT in various clinical scenario and shines light to the HDR BRT rationale, as an ultimately conformal dose delivery method enabling safe dose escalation to the prostate. Conclusion:Valid long-term data, both in regard to the oncologic outcomes and toxicity profile, support the current clinical indication spectrum of HDR BRT. At the same time, this serves as solid, rigid ground for emerging therapeutic applications, allowing the technique to remain in the spotlight alongside stereotactic radiosurgery.

show abstract

Accuracy of an in vivo dosimetry‐based source tracking method for afterloading brachytherapy — A phantom study

et al. 2021

View full text Add to dashboard Cite

To report on the accuracy of an in vivo dosimetry (IVD)-based source tracking (ST) method for high dose rate (HDR) prostate brachytherapy (BT). Methods: The ST was performed on a needle-by-needle basis. A least square fit of the expected to the measured dose rate was performed using the active dwell positions in the given needle. Two fitting parameters were used to determine the position of each needle relative to the IVD detector: radial (away or toward the detector) and longitudinal (along the axis of the treatment needle). The accuracy of the ST was assessed in a phantom where the geometries of five HDR prostate BT treatments previously treated at our clinic were reproduced. For each of the five treatment geometries, one irradiation was performed with the detector placed in the middle of the implant. Furthermore, four additional irradiations were performed for one of the geometries where the detector was retracted caudally in four steps of 10-15 mm and up to 12 mm inferior of the most inferior active dwell position, which represented the prostate apex. The time resolved dose measurements were retrieved at a rate of 20 Hz using a detector based on an Al 2 O 3 :C radioluminescence crystal, which was placed inside a standard BT needle. Individual calibrations of the detector were performed prior to each of the nine irradiations.Results: Source tracking could be applied in all needles across all nine irradiations. For irradiations with the detector located in the middle region of the implant (a total of 89 needles), the mean AE standard deviation (SD, k = 1) accuracy was −0.01 mm AE 0.38 mm and 0.30 mm AE 0.38 mm in the radial and longitudinal directions, respectively. Caudal retraction of the detector did not lead to reduced accuracy as long as the detector was located superior to the most inferior active dwell positions in all needles. However, reduced accuracy was observed for detector positions inferior to the most inferior active dwell positions which corresponded to detector positions in and inferior to the prostate apex region. Detector positions in the prostate apex and 12 mm inferior to the prostate resulted in mean AE SD (k = 1) ST accuracy of 0.7 mm AE 1 mm and 2.8 mm AE 1.6 mm, respectively, in radial direction, and −1.7 mm AE 1 mm and −2.1 mm AE 1.1 mm, respectively, in longitudinal direction. The largest deviations for the configurations with those detector positions were 2.6 and 5.4 mm, respectively, in the radial direction and −3.5 and −3.8 mm, respectively, in the longitudinal direction. Conclusion: This phantom study demonstrates that ST based on IVD during prostate BT is adequately accurate for clinical use. The ST yields submillimeter accuracy on needle positions as long as the IVD detector is positioned superior to at least one active dwell position in all needles. Locations of the detector inferior to the prostate apex result in decreased ST accuracy while detector locations in the apex region and above are advantageous for clinical applications.

show abstract

High dose rate brachytherapy as monotherapy for localised prostate cancer

Cited by 35 publications

References 34 publications

Investigating the role of constrained CVT and CVT in HIPO inverse planning for HDR brachytherapy of prostate cancer

Investigating the role of constrained CVT and CVT in HIPO inverse planning for HDR brachytherapy of prostate cancer

High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome

Accuracy of an in vivo dosimetry‐based source tracking method for afterloading brachytherapy — A phantom study

Contact Info

Product

Resources

About